Treatment of CLL and the Value of Testing for Minimal Residual Disease (MRD) 

The goal of this activity is to improve knowledge of clinical trial data and best practices on the use of minimal residual disease (MRD) in the management of patients with CLL.

Agenda:

7:00-7:00  Welcome and Introduction  – Anna Schuh, MD, PhD

7:00-7:05  What is MRD and Why is it Important?   – Anna Schuh, MD, PhD

7:05-7:15  How is MRD Measured?  – Anna Schuh, MD, PhD

7:15-7:25  Clinical Data with MRD Testing – Anna Schuh, MD, PhD

7:25-7:40  Integrating MRD Testing Into Clinical Practice  – Javier Pinilla-Ibarz, MD, PhD

7:40-7:50  The Future of MRD Analysis in CLL  – Javier Pinilla-Ibarz, MD, PhD

7:50-8:00  Q&A                                                                                       

 

Faculty:

Anna Schuh, MD, PhD
Director of Molecular Diagnostics
Oxford NHS/BRC Molecular Diagnostics Centre 
University of Oxford
Oxford, UK

Javier Pinilla-Ibarz, MD, PhD
Director of Immunotherapy, Malignant Hematology Division 
H. Lee Moffitt Cancer Center & Research Institute 
Assistant Professor, Department of Oncologic Sciences 
University of South Florida 
Tampa, FL

 

Supported by Adaptive Biotechnologies, Inc. This satellite symposium is not endorsed by the iwCLL. Not part of the official iwCLL 2019.

 

Register Now!